The Latest on the Biopharmaceutical Industry’s Efforts to Beat Coronavirus

Read About Member Efforts
America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus. In addition to applying their scientific expertise to find ways to diagnose, treat and prevent infections from the virus, the biopharmaceutical industry is providing financial support and in-kind donations to organizations and collaborating with U.S. and global health authorities to combat this global public health emergency. More than half of PhRMA members have R&D for potential treatments and vaccines unde way or are providing donations of medicines and critical medical supplies as well as providing financial donations to support patients and first responders in addressing this evolving crisis.
×
Our Commitment
Our Commitment to Beat Coronavirus
In these unprecedented times, we are coming together to achieve one shared goal: to beat COVID-19. The decades-long investments we have made in new technology, research and treatments have prepared us to act swiftly:
Small drop being dropped into test tube
We are rapidly screening our vast global libraries of medicines to identify potential treatments and have numerous clinical trials underway to test new and existing therapies.
Doctors walking down a well lit hallway
We are dedicating our top scientists and using our investments in new technologies to speed the development of safe and effective vaccines.
Doctor taking readings from instruments on a wall
We are sharing the learnings from clinical trials in real time with governments and other companies to advance the development of additional therapies.
Bottles of medicines in a manufacturing setting
We are expanding our unique manufacturing capabilities and sharing available capacity to ramp up production once a successful medicine or vaccine is developed.
Women wearing a mask crossing a crosswalk amongst others in masks
We are collaborating with government agencies, hospitals, doctors and others to donate supplies and medicines to help those affected around the world.
Computer open with stethoscope right along side
We are working with governments and insurers to ensure that when new treatments and vaccines are approved they will be available and affordable for patients.

We all have unique roles to play and are confident that together we will be successful. And we won't rest until we are.

Download the Biopharmaceutical Industry Principles on Beating Coronavirus
Download the Fact Sheet on Helping those Affected by the Coronavirus
Related

Related Resources

Doing Our Part to Fight Coronavirus

watch video>
Just as you are doing your part to fight the novel coronavirus, America's Biopharmaceutical Companies are working around the clock to fight COVID-19.

Video: Biopharmaceutical Innovation Fighting COVID-19

watch video>
America's biopharmaceutical companies are working together to end the COVID-19 pandemic. Watch here to see the five big ways they are tackling the virus right now.

The Biopharmaceutical Industry is Leading the Way in Developing New Vaccines and Treatments for COVID-19

fact sheet>
America’s biopharmaceutical companies are committed to developing solutions to help diagnose, treat and prevent COVID-19, a disease caused by a novel strain of coronavirus.

PhRMA @ Home

Watch Videos>
Click or tap for a collection of video sessions with experts from PhRMA commenting on various aspects of ongoing PhRMA member company efforts to support the detection, prevention and treatment of the coronavirus outbreak.
default_1000x635_link

A Step-by-Step Breakdown of How Scientists Plan to Develop a Coronavirus Vaccine.

Read More>
Step by step, here’s how scientists are aiming to develop a vaccine for COVID-19.

Working Together to Fight COVID-19

graphic>
America’s biopharmaceutical companies have joined forces to fight COVID-19.

PhRMA Open Letter: To the Millions Affected by COVID-19

read more>
In these unprecedented times, it can be hard to feel optimistic, but there are reasons to stay positive.

New report shows nearly 260 vaccines in development, including dozens for COVID-19

Blog Post>
In the United States today, 16 diseases are now preventable as a result of childhood vaccines, and routine immunization of U.S. children born between 1994-2018 has prevented more than 419 million illnesses.

The continued imperative to protect U.S. innovation worldwide

Blog Post>
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are collaborating with others and working around the clock to research and develop vaccines and treatments to beat the virus.

COVID-19 Response: Supporting the frontline

Blog Post>
America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19. We are working around the clock to research and develop new vaccines and treatments, as well as testing existing medicines to help those infected with the virus. In addition, our companies are committed to supporting health care workers who are on the frontlines and communities around the world affected by COVID-19.

Guest Post: What will we learn from COVID-19?

Blog Post>
It has been amazing to see our scientific and health care communities mobilizing during these extraordinary times. Such is the devastating human toll and global impact of COVID-19 that developing tests, treatments and vaccines has become an urgent, unifying priority for health care providers, policymakers and the biopharmaceutical community alike.

Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19

Blog Post>
As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for the next public health emergency: Antimicrobial resistance (AMR).

Guest post: Takeda’s efforts to address COVID-19

Blog Post>
Takeda is closely monitoring the novel coronavirus (COVID-19) outbreak and the global response. As a company dedicated to the health and well-being of people around the globe, we are committed to taking steps to help those impacted by the coronavirus.

Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines

Blog Post>
As biopharmaceutical companies continue to fight COVID-19 through research and development, three companies have teamed up to create programs empowering employees with medical and laboratory expertise to completely or partially pause their current roles and volunteer their medical skills to help their local health care organizations.

Guest Post: Looking Out for the Invisibly Vulnerable in the Time of COVID-19

Blog Post>
The global COVID-19 outbreak has upended our regular routines, shut down our schools and workplaces, and made terms like “social distancing” and “flatten the curve” part of our everyday conversations.

The biopharmaceutical industry’s unique role in responding to COVID-19

Blog Post>
As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States, both the private and public sectors are working around the clock to find solutions.

Industry Commitment to Combating Coronavirus Print Ad

see more>
In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: the eradication of COVID-19. The decades-long investments we made in new technology, research and treatments have prepared us to act swiftly.

How Biopharmaceutical Science Is Fighting Back Against the Coronavirus

read more>
As people across the globe continue to be impacted by COVID-19, the disease caused by a new strain of coronavirus, biopharmaceutical companies have rapidly taken action to research and develop potential new medicines, while partnering with public health leaders worldwide, to combat this global public health emergency.
default_1000x635_link

Stephen Ubl: In Pursuit of Coronavirus Treatments and Vaccines

Read More>
Developing vaccines and treatments for pandemics is challenging. While our industry is best-positioned to find an effective vaccine and treatment and is doing just that, we also continue to collaborate with government agencies, like the NIH and BARDA, to better understand the trajectory of the virus and work collectively to address this public health emergency.

Helping those affected by the coronavirus

Blog Post>
America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a novel strain of coronavirus. In addition to applying their scientific expertise to find ways to diagnose, treat and prevent infections from the virus, the biopharmaceutical industry is providing financial support and in-kind donations to organizations and collaborating with U.S., Chinese, and global health authorities to combat this global public health emergency.

Impact of Industry Sponsored Clinical Trials

read more>
The biopharmaceutical industry brings profound value to patients through new treatments and cures for society’s most devastating and costly diseases and conditions, providing millions of patients with treatment options they would not otherwise have.
default_1000x635_link

From the CDC: Preventing COVID-19 Spread in Communities

Read More>
CDC Community Mitigation Framework: Actions that individuals, businesses, health departments, and community settings (such as schools) can take to slow the spread of COVID-19.

PhRMA Coronavirus Print Ads

read more>
Visit here to view and download PhRMA's print ads about how America's biopharmaceutical companies are working to get life back to normal after the coronavirus pandemic.